Influence of microalbuminuria in achieving blood pressure goals
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: In all individuals with hypertension regardless of diabetes status, microalbuminuria is an independent risk marker for cardiovascular events including myocardial infarction, stroke and other conditions. While blood pressure reduction is important in reducing this marker in individuals with hypertension other factors such as salt intake play an important role in reducing oxidant stress and other factors related to the genesis of microalbuminuria. RECENT FINDINGS: Clinical trials demonstrate that drugs interfering with the renin-angiotensin system--angiotensin-converting enzyme inhibitors and angiotensin receptor blockers--should be used as first-line antihypertensive therapy in patients with microalbuminuria because they seem to have a blood pressure-independent antiproteinuric effect. A combination of an angiotensin-converting enzyme inhibitor with an angiotensin receptor blocker or other classes of medications shown to decrease protein excretion, such as nondihydropyridine calcium antagonists or aldosterone receptor blockers, should be considered to decrease albuminuria further; beta-blockers with alpha-blocking properties such as carvedilol have also been shown to reduce microalbuminuria probably secondary to its antioxidant properties. SUMMARY: This review provides a summary of current evidence regarding the associations of blood pressure with microalbuminuria, the rationale for currently recommended blood pressure goals, and the use of various classes of antihypertensive agents in proteinuric patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 20% develop end-stage kidney disease and almost all will have severely increased albuminuria despite achievement of blood pressure goals (484).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [484]
In the citing paper
“Another factor that indicates progression is an increase in albuminuria from stage A2 to A3 over time despite achievement of blood pressure goals (342).”
From Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (2011) · cites this paper as [342]
Citations
Cites
1 retracted
Rachmani, R., Slavachevsky, I., Amit, M., Levi, Z., Kedar, Y., Berla, M., & Ravid, M. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01194.x · Cited by 142
RetractedBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Preserving renal function in adults with hypertension and diabetes: A consensus approach
Bakris, G. L., Williams, M., Dworkin, L., Elliott, W. J., Epstein, M., Toto, R., Tuttle, K., Douglas, J., Hsueh, W., & Sowers, J. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.16225 · Cited by 1,411
Self-citationMogensen, C. E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R., Watts, R. W., & Cooper, M. E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1440 · Cited by 1,037
Preventing Microalbuminuria in Type 2 Diabetes
Ruggenenti, P., Fassi, A., Ilieva, A. P., Bruno, S., Iliev, I. P., Brusegan, V., Rubis, N., Gherardi, G., Arnoldi, F., Ganeva, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042167 · Cited by 1,020
Bakris, G. L., Fonseca, V., Katholi, R. E., McGill, J. B., Messerli, F. H., Phillips, R. A., Raskin, P., Wright, J. T., Oakes, R., Lukas, M. A., et al. (2004) · JAMA · doi:10.1001/jama.292.18.2227 · Cited by 792
Self-citationCasas, J. P., Chua, W., Loukogeorgakis, S., Vallance, P., Smeeth, L., Hingorani, A. D., & MacAllister, R. J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67814-2 · Cited by 745
Kunz, R., Friedrich, C., Wolbers, M., & Mann, J. F. E. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-1-200801010-00190 · Cited by 717
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466
Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Epstein, M., Williams, G. H., Weinberger, M., Lewin, A., Krause, S., Mukherjee, R., Patni, R., & Beckerman, B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00240106 · Cited by 459
INCREASED URINARY ALBUMIN-EXCRETION RATE IN BENIGN ESSENTIAL HYPERTENSION
Parving, H.-H., Mogensen, C. E., Jensen, H. Æ., & Evrin, P.-E. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91002-2 · Cited by 409
Viberti, G. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510280037029 · Cited by 381
Diurnal Variations of Blood Pressure and Microalbuminuria in Essential Hypertension
Bianchi, S., Bigazzi, R., Baldari, G., Sgherri, G., & Campese, V. M. (1994) · American Journal of Hypertension · doi:10.1093/ajh/7.1.23 · Cited by 369
Ravid, M. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440030080010 · Cited by 314
H. Bennett, P., Haffner, S., Kasiske, B. L., Keane, W. F., Mogensen, C. E., Parving, H.-H., Steffes, M. W., & Striker, G. E. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90636-3 · Cited by 297
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy
Bakris, G. L., Weir, M. R., Dequattro, V., & McMahon, F. G. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00083.x · Cited by 276
Self-citationTreatment of arterial hypertension in diabetic humans: Importance of therapeutic selection
Bakris, G. L., Barnhill, B. W., & Sadler, R. (1992) · Kidney International · doi:10.1038/ki.1992.139 · Cited by 219
Self-citationHermans, M. M. H., Henry, R., Dekker, J. M., Kooman, J. P., Kostense, P. J., Nijpels, G., Heine, R. J., & Stehouwer, C. D. A. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006111217 · Cited by 196
Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension
Agrawal, B., Berger, A., Wolf, K., & Luft, F. C. (1996) · Journal of Hypertension · doi:10.1097/00004872-199602000-00011 · Cited by 191
van den Meiracker, A. H., Baggen, R. G., Pauli, S., Lindemans, A., Vulto, A. G., Poldermans, D., & Boomsma, F. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000249708.44016.5c · Cited by 187
Han, S.-Y., Kim, C.-H., Kim, H.-S., Jee, Y.-H., Song, H.-K., Lee, M.-H., Han, K.-H., Kim, H.-K., Kang, Y.-S., Han, J.-Y., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005111196 · Cited by 172
Giaconi, S., Levanti, C., Fommei, E., Innocenti, F., Seghieri, G., Palla, L., Palombo, C., & Ghione, S. (1989) · American Journal of Hypertension · doi:10.1093/ajh/2.4.259 · Cited by 168
Bigazzi, R., Bianchi, S., Campese, V. M., & Baldari, G. (1992) · Nephron · doi:10.1159/000186842 · Cited by 162
Redón, J., Liao, Y., Lozano, J. V., Miralles, A., Pascual, J. M., & Cooper, R. (1994) · PubMed · Cited by 141
Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension
Cerasola, G., Cottone, S., Mulè, G., et al. (1996) · Journal of Hypertension · doi:10.1097/00004872-199607000-00016 · Cited by 128
Böhlen, L., de Courten, M., & Weidmann, P. U. (1994) · American Journal of Hypertension · doi:10.1093/ajh/7.9.84s · Cited by 119
Smith, A. C., Toto, R. D., & Bakris, G. L. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00055.x · Cited by 117
Self-citationRedon, J., Liao, Y., Lozano, J. V., Miralles, A., Pascual, J. M., & Cooper, R. S. (1994) · Journal of Hypertension · doi:10.1097/00004872-199408000-00013 · Cited by 112
The Predictive Value of Microalbuminuriq in IPPM: A five-year follow-up study
Almdal, T., Nörgaard, K., Feldt-Rasmussen, B., & Deckert, T. (1994) · Diabetes Care · doi:10.2337/diacare.17.2.120 · Cited by 104
Factors Related to the Presence of Microalbuminuria in Essential Hypertension
Redón, J., Liao, Y., Lozano, J. V., Miralles, A., Baldó, E., & Cooper, R. (1994) · American Journal of Hypertension · doi:10.1093/ajh/7.9.801 · Cited by 94
Al-Kateb, H., Boright, A. P., Mirea, L., Xie, X., Sutradhar, R., Mowjoodi, A., Bharaj, B., Liu, M., Bucksa, J. M., Arends, V. L., et al. (2008) · Diabetes · doi:10.2337/db07-1059 · Cited by 93
Equiluz‐Bruck, S., Schnack, C., KOPP, H., & Schernthaner, G. (1996) · American Journal of Hypertension · doi:10.1016/0895-7061(96)00302-0 · Cited by 83
Differential Effects of β-Blockers on Albuminuria in Patients With Type 2 Diabetes
Bakris, G. L., Fonseca, V., Katholi, R. E., McGill, J. B., Messerli, F., Phillips, R. A., Raskin, P., Wright, J. T., Waterhouse, B., Lukas, M. A., et al. (2005) · Hypertension · doi:10.1161/01.hyp.0000190585.54734.48 · Cited by 82
Self-citationKhosla, N., Sarafidis, P. A., & Bakris, G. L. (2006) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2006.06.005 · Cited by 62
Self-citationRossi, M. C., Nicolucci, A., Pellegrini, F., Comaschi, M., Ceriello, A., Cucinotta, D., Giorda, C. B., Valentini, U., Vespasiani, G., & Cosmo, S. D. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm798 · Cited by 55
New insights into the significance of microalbuminuria
MacIsaac, R. J., Jerums, G., & Cooper, M. E. (2003) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200401000-00012 · Cited by 54
Christensen, C. (1983) · Journal of Hypertension · doi:10.1097/00004872-198306000-00008 · Cited by 46
Zhang, Z., Shahinfar, S., Keane, W. F., Ramjit, D. R., Dickson, T. Z., Gleim, G. W., Mogensen, C. E., de Zeeuw, D., Brenner, B. M., & Snapinn, S. M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080632 · Cited by 39
Pontremoli, R., Cheli, V., Sofia, A., et al. (1995) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/10.supp6.6 · Cited by 38
West, J. N. W., Gosling, P., Dimmitt, S. B., & Littler, W. A. (1991) · Clinical Science · doi:10.1042/cs0810373 · Cited by 38
Should β-Blockers Be Used to Control Hypertension in People With Chronic Kidney Disease?
Hart, P. D., & Bakris, G. L. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.07.003 · Cited by 34
Self-citationAntioxidant and antiinflammatory effect of carvedilol in mononuclear cells of hypertensive patients
Calò, L. A., Semplicini, A., & Davis, P. A. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.05.030 · Cited by 34
James, M. A., Fotherby, M. D., & Potter, J. F. (1995) · Clinical Science · doi:10.1042/cs0880185 · Cited by 32
Giordano, M., Sanders, L. R., Castellino, P., CANESSA, M. L., & DeFronzo, R. A. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000188911 · Cited by 25
Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects*
Dominguez, L. J., Barbagallo, M., Kattah, W., García, D. L., & Sowers, J. R. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)00143-d · Cited by 23
Albumin Excretion Rate and Metabolic Modifications in Patients With Essential Hypertension
Puig, J., Mateos, F., Ramos, T. H., et al. (1994) · American Journal of Hypertension · doi:10.1093/ajh/7.1.46 · Cited by 19
Reams, G. P., Lau, A., Knaus, V. L., et al. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb04668.x · Cited by 10
Spangler, J. G., Bell, R. A., Summerson, J. H., et al. (1997) · PubMed · Cited by 7
ANTIPROTEINURIC EFFECT OF ACE INHIBITORS
Heeg, J. E., de Zeeuw, D., & de Jong, P. E. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90843-4 · Cited by 5
Research works printed but not linked: 1
- Spangler, 1997, J Am Board Fam Pract, 10, 180
Cited by
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.161596 · Cited by 1,360
Self-citationSacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Diabetes Care · doi:10.2337/dc11-9998 · Cited by 718
Self-citationBakris, G. L., Sarafidis, P. A., Weir, M. R., Dahlöf, B., Pitt, B., Jamerson, K., Velazquez, E. J., Staikos-Byrne, L., Kelly, R. Y., Shi, V., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62100-0 · Cited by 523
Self-citationSacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
“Another factor that indicates progression is an increase in albuminuria from stage A2 to A3 over time despite achievement of blood pressure goals (342).”
Self-citation
Metadata
- Authors
- Duka, I., & Bakris, G.
- Affiliations
- University of Chicago (US)
- Corresponding author
- Bakris, George
- ORCID
- Bakris, George
- Venue
- Current Opinion in Nephrology and Hypertension
- Published
- 2008-09
- Volume
- 17
- Issue
- 5
- Pages
- 457-463
- ISSN
- 1062-4821 (ISSN-L)
- OpenAlex
- W2022552502
- Semantic Scholar
- 0b011a7fcf70a8e7dc78c4c2e284881a3843d4a3
- Cited by
- 18
- References
- 54
- Citations by year
- 2025: 1 · 2023: 3 · 2016: 1 · 2013: 2 · 2012: 1
- FWCI
- 0.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Nephrology & Hypertension (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- microalbuminuria, blood pressure targets, hypertension, renin-angiotensin system, ACE inhibitors, angiotensin receptor blockers, antiproteinuric effect, salt intake, oxidative stress, aldosterone receptor blockers, carvedilol, beta-blockers, antihypertensive therapy, cardiovascular risk
- MeSH terms
- Albuminuria, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Humans, Hypertension, Risk Factors, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.